Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.39 |
| ▸ | CA1 | P00915 | 12/20 | 0.39 |
| ▸ | CA9 | Q16790 | 11/20 | 0.39 |
| ▸ | CA12 | O43570 | 9/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888769 | 0.93 | S1PR1 (0.38) | S1PR1TP53 | |
| SCHEMBL4890499 | 0.90 | ALDH1A1 (0.45) | S1PR1 | |
| SCHEMBL4880805 | 0.83 | MAPT (0.42) | TP53 | |
| SCHEMBL4888547 | 0.82 | CTSS (0.42) | CA2CA1CA9CA12CA14 | |
| SCHEMBL4886294 | 0.81 | NPC1 (0.45) | TP53 | |
| SCHEMBL4888764 | 0.74 | CTSS (0.43) | TP53 | |
| SCHEMBL4884701 | 0.74 | SMN1; SMN2 (0.41) | CA2CA1CA9CA12TP53 | |
| SCHEMBL4891054 | 0.71 | CA9 (0.49) | CA2CA1CA9CA12S1PR1 | |
| SCHEMBL4891052 | 0.71 | CA9 (0.51) | CA2CA1CA9CA12S1PR1 | |
| SCHEMBL4890495 | 0.70 | CTSS (0.52) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CA2 513/4885CA1 2389/4885CA9 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.